Related Experiment Video
Updated: Jun 25, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys
B'Ann True Gabelt1, Elizabeth A Hennes, Mark A Bendel
1Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin 53705-2135, USA.
Summary
Combining prostaglandin (PG) subtype agonists effectively lowers intraocular pressure (IOP) in monkeys. This strategy shows potential for developing potent antiglaucoma treatments by mimicking the effects of PGF(2a)-isopropyl ester.
Area of Science:
- Ophthalmology
- Pharmacology
- Glaucoma Research
Background:
- Prostaglandin (PG) F(2a)-isopropyl ester (PGF(2a)-ie) effectively lowers intraocular pressure (IOP).
- Investigating whether combining PG-subtype-selective compounds can replicate PGF(2a)-ie's IOP-lowering efficacy is crucial for glaucoma treatment development.
Purpose of the Study:
- To determine if combining various prostaglandin (PG) subtype-selective agonists can reproduce the intraocular pressure (IOP)-lowering response seen with PGF(2a)-isopropyl ester (PGF(2a)-ie).
- To evaluate the individual and combined effects of FP, EP1, EP2, and EP3 agonists on IOP in normotensive monkeys.
Main Methods:
- Topical administration of selective prostaglandin (PG) subtype agonists, including latanoprost (FP), bimatoprost (prostamide), travoprost (FP), butaprost (EP2), 17-phenyl trinor PGE2 (EP1), and sulprostone (EP3), in normotensive monkeys.
- Assessment of intraocular pressure (IOP) reduction following monotherapy and combination therapy with these PG agonists.
- Comparison of IOP-lowering effects with PGF(2a)-isopropyl ester (PGF(2a)-ie).
Main Results:
- Latanoprost, bimatoprost, and travoprost (FP agonists) each lowered IOP by approximately 25% with once-daily (q.d.) administration.
- The EP2 agonist, butaprost, showed a modest IOP-lowering effect, while EP1 and EP3 agonists had no significant effect individually.
- A combination of latanoprost (FP), 17-phenyl trinor PGE2 (EP1), butaprost (EP2), and sulprostone (EP3) achieved a 50-55% IOP reduction, comparable to PGF(2a)-ie.
Conclusions:
- Single-agent FP agonists like latanoprost, travoprost, and bimatoprost demonstrate significant IOP-lowering effects in monkeys, most effective when administered once daily.
- Combining PG-subtype agonists (FP, EP1, EP2, EP3) can achieve a potent IOP-lowering response similar to PGF(2a)-ie.
- Combination therapy with PG-subtype agonists represents a promising strategy for developing more effective antiglaucoma treatments.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.